z-logo
Premium
Predominant factors associated with bone loss in liver transplant patients – after prolonged post‐transplantation period
Author(s) -
Segal Elena,
Baruch Yakov,
Kramsky Rimma,
Raz Batia,
Tamir Ada,
IshShalom Sophia
Publication year - 2003
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1034/j.1399-0012.2003.02065.x
Subject(s) - medicine , femoral neck , prednisone , liver transplantation , transplantation , tacrolimus , osteoporosis , vitamin d and neurology , bone mineral , glucocorticoid , gastroenterology , bone density , surgery , endocrinology , urology
 Introduction: Osteoporosis is a major cause of morbidity in liver transplant recipients and is associated with multiple factors. Objectives: To evaluate bone mineral density (BMD), bone turnover and calcium‐regulating hormones in 29 patients (17 men, 12 women) 2–12 yrs following liver transplantation for non‐alcoholic liver diseases. Results: Fifteen patients (52%) were on immunosuppressive treatment with tacrolimus and 14 (48%) with cyclosporine. Eleven patients (38%) were currently on prednisone, 18 patients (62%) had stopped glucocorticoid treatment 6 months to 11 yrs prior to the study. Nineteen patients (65.5%) had decreased BMD according to WHO criteria, 17 (58.2%) at the femoral neck, 13 (44.8%) at the lumbar spine. Nineteen patients (65.5%) had a subnormal (<15 ng/mL) serum level of 25 (OH) D3. These patients had significantly lower BMD at the femoral neck (p = 0.02). Femoral neck BMD negatively correlated with serum parathyroid hormone level (p = 0.06, r  = −0.35), length of the post‐transplantation period (p = 0.025, r  = −0.416) and duration of glucocorticoid treatment (p = 0.029, r  = −0.406), regardless of its cumulative dose. Symptomatic fractures were less frequent in tacrolimus treated patients than in cyclosporine users (p = 0.03). Conclusions:  Decreased BMD is frequent following liver transplantation and is affected by vitamin D deficiency, cyclosporine use, and the duration of glucocorticoid therapy, but not by its cumulative dose. Achievement and maintenance of optimal vitamin D status and shortening of glucocorticoid treatment period may have a favorable effect on bone preservation.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom